Secret Shopper Study Exposes Risky Online GLP-1 Prescribing Practices
Two-thirds of online GLP-1 sellers approved prescriptions without clinician interaction, raising serious safety and financial harm concerns.
Summary
A secret shopper study published in JAMA tested 49 online platforms selling GLP-1 receptor agonists — the popular class of drugs used for obesity and diabetes. Researchers found that two-thirds did not require any clinician interaction before issuing a prescription. Most relied solely on patient questionnaires, and some issued prescriptions in under five minutes. Four platforms offered no way to ask a clinician any questions at all. Researchers from Yale warned that this minimal oversight increases risks of dangerous drug interactions, missed medical histories, and financial harm. Nearly 20% of adults currently using GLP-1 medications obtained them online, making these findings broadly relevant to anyone considering this route for weight or metabolic management.
Detailed Summary
GLP-1 receptor agonists have rapidly become some of the most sought-after medications in modern medicine, used to treat obesity and type 2 diabetes. With limited insurance coverage, high demand, and ongoing drug shortages, millions of patients have turned to online telehealth platforms to access these drugs. A new secret shopper study published in JAMA now raises serious concerns about the safety standards of these platforms.
Researchers at Yale University tested 49 online GLP-1 sellers between August and December 2025. A simulated patient profile meeting standard eligibility criteria was used to navigate each platform's prescription process. The results were striking: 91.8% of websites approved a prescription, and 69.4% mailed the medication. The median time to receive a prescription was one day or less, and two websites issued prescriptions in under five minutes.
Only 13 of the 49 platforms required a video visit, and just three required a phone call — typically lasting under 10 minutes. Four platforms offered no opportunity whatsoever to interact with a clinician. Every website used a questionnaire, but researchers warned these tools often fail to capture crucial clinical and social histories necessary for safe prescribing.
A particularly alarming finding was that the same doctor appeared to prescribe the medication across multiple platforms to the same simulated patient — suggesting inadequate cross-platform oversight. Prescribers on these platforms also lack access to patients' electronic health records, meaning potential drug interactions or contraindicated conditions could easily be missed.
For health-conscious adults considering GLP-1 therapy, the practical takeaway is clear: consult a primary care physician or endocrinologist who has access to your full medical history. Online convenience should not come at the cost of clinical safety. The researchers advised patients with an established clinician to seek prescriptions through that relationship rather than through low-oversight telehealth platforms.
Key Findings
- Two-thirds of 49 online GLP-1 platforms approved prescriptions without requiring any clinician interaction.
- Four websites offered zero opportunity for patients to ask a clinician any questions before prescribing.
- 91.8% of tested platforms approved a prescription; two issued them in under five minutes.
- The same doctor prescribed to the simulated patient across multiple platforms, signaling dangerous oversight gaps.
- Nearly 20% of current GLP-1 users obtained their prescription online, per a KFF poll.
Methodology
This is a news report summarizing a peer-reviewed secret shopper study published in JAMA. The study used a simulated patient methodology across 49 online GLP-1 platforms, which is a recognized investigative approach but has inherent limitations in generalizing to real patient experiences.
Study Limitations
The study used a single simulated patient profile, which may not reflect the full range of screening rigor applied to real patients with complex histories. The article is a news summary and does not reproduce the full JAMA study data; readers should consult the primary publication for complete methodology and findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: